DIA: Driving Insights to Action
Science:Life Sciences
Japan, the world’s third largest pharmaceutical market, has long been engaged in clinical research in every therapeutic area. “COVID-19 totally changed the world. The remote connection is the only way for the CRAs and the sites to communicate and work together, so both the sponsors and the sites started using remote communication or remote monitoring gradually,” explains Eri Sekine, Region Head of Trial Monitoring Japan, Global Development Operations, Novartis Pharma KK, Japan. “So now it's the time to consider how to utilize modern technologies in clinical trials. I think, based on our experience, that people will start thinking more aggressively about digitalization, digital solutions, to make clinical trials easier for sites, sponsors, and for patients.”
DIAmond Session 203: “Innovation is Clearly Happening”: Next Generation Collaboration: Transforming the Industry
DIAmond Session 201: International Regulatory Convergence, Collaboration & Cooperation
Executive FDA Leadership Reviews & Previews PDUFA Reauthorization
“Biosimilars have at last come of age in the United States”
Mission, History & Opportunity Attracts New DIA Americas Leadership
Clinical & Real-World Data: Is AI the Missing Link?
TransCelerate Moves Clinical QMS from Vision to Conceptual Framework
Executive Director Shares New CTTI Strategic Plan to Improve Clinical Trials
Who Determines the Price of Medicines – and How?
“An Urgent Imperative Now to Learn Quickly”: DIA 2016 Co-Chair Dr. Gigi Hirsch
Industry-Patient Relations: Culture Change or Culture Shock?
Every Journey Begins with a First Step: DIA Patient Engagement
“Outbreaks are inevitable. Pandemics are preventable.” – DIA 2016 Keynote Speaker Dr. Larry Brilliant
Growing Irrelevancy of Pre- versus Post-Market Divide for EU Medical Devices
Crossroads in Europe: Access from a Market and HTA Perspective
A Visionary Takes the Helm at DIA Europe, Middle East & Africa (DIA EMEA)
Steps to Meet the “Big Quality” Challenge of “Big Data”
Innovation: Can it Span the “Efficacy versus Effectiveness Gap”?
Dr. Kemal Malik Ponders “Is Innovation Always the Answer?”
EMA Senior Medical Officer Explains “Access versus Evidence Tradeoff”
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Raising Health